Crossbeta gains new ceo and funding
Dutch biotech to advance technology in several therapeutic areas
Scheefhals has joined the biotech firm from Avantium, where he held several managerial positions, most recently as chief operating officer of the pharma business unit. Prior to Avantium, he held commercial positions at DSM Biologics, Analytico and NPBI, which is now part of Fresenius.
Scheefhals replaces Johan Renes, who steps down after being with the company from the start and for the past two years as part-time ceo.
Crossbeta has recently won funding of €2m, which will be used to advance the firm’s technology in several therapeutic areas and to establish a stronger position for co-development programmes and commercialisation partnerships.
You may also like
Research & Development
Nuclera and University of Cambridge researchers demonstrate rapid structural analysis of challenging drug target
Collaboration combines cell-free protein synthesis, proprietary nanodisc technology and cryo-electron microscopy (cryo-EM) for high-resolution structural analysis of a G protein-coupled receptor (GPCR)
Cleaning
Guardtech partner with Intense Pulsed Light innovators Biopulz to offer game-changing new cleanroom decontamination solution
New partnership will give Guardtech clients access to Biopulz’s mobile Eloane tower and integrated E-z̈o IPL decontamination system as part of their cleanroom installation projects
Research & Development
Evotec secures $2.9m grant to advance stem cell-based drug safety testing
The three-year Gates Foundation grant will support Evotec's human induced pluripotent stem cell platform, helping global health researchers identify potential developmental toxicity risks earlier in drug discovery